Overview
TRIO is an academic clinical research organization focused on translating cancer science into patient treatments. It coordinates translational cancer research by bringing innovative, targeted therapeutic ideas into clinical trials. The group operates through an international network, with offices in Canada, France, and Uruguay and partnerships with about 2,000 investigators and 450 cancer centers in more than 45 countries, allowing global studies of systemic cancer therapies. Compared with typical biotech or pharma firms, TRIO emphasizes academic collaboration and real-world trial execution across many centers rather than developing and selling drugs itself. Its goal is to move promising cancer treatments from the lab to the clinic, testing them in trials to improve outcomes for patients.
Work here?Claim your company
Simplify's take
What believers are saying
- TRIO ranked among Uruguay’s best workplaces in 2025 for the third straight year.
- TRIO added Stanford’s Mark Pegram to its breast cancer scientific committee in 2025.
- TRIO is actively hiring in 2026, signaling continued sponsor demand and execution.
What critics are saying
- Revelio says TRIO headcount fell to 281 in 2026 from 294 in 2023.
- TRIO has no disclosed funding, making sponsor concentration a hidden revenue risk.
- If NATALEE-like wins stop, larger CROs can capture biotech and pharma oncology trials.
What makes Translational Research in Oncology unique
- TRIO’s NATALEE trial helped win FDA adjuvant ribociclib approval in 2024.
- Its 2,000 investigators and 450 centers enable rapid multinational oncology enrollment.
- Dennis Slamon’s scientific leadership anchors credibility with top academic cancer centers.
Help us improve and share your feedback! Did you find this helpful?